The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds, according to the company.

VenBio said it will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals for unmet medical needs. Since 2011, VenBio reports it has raised nearly $1.5 billion in capital commitments.

Interline raises $92M for drug discovery of dysfunctional proteins
Interline Therapeutics has raised $92 million to be used to expand its research platform and advance six preclinical therapeutic programs.

Jaguar Gene Therapy nabs $139M to develop AAV9-based gene therapies
Jaguar Gene Therapy has closed $139 million in funding to advance its preclinical pipeline of adeno-associated virus 9 (AAV9)-based gene therapies.

Alloy raises $75M to advance biologics discovery platforms
Biotechnology ecosystem company Alloy Therapeutics announced it has closed $75 million in series C funding.

Chime secures $190M to expand biopharma manufacturing
China-based contract development and manufacturing organization Chime Biologics has secured $190 million to finance the second phase of its biomanufacturing...

Insightful Science to acquire Dotmatics
Global life sciences software developer Insightful Science plans to acquire cloud-based scientific data management firm Dotmatics of the U.K.